A detailed history of Kayne Anderson Rudnick Investment Management LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Kayne Anderson Rudnick Investment Management LLC holds 14 shares of CRSP stock, worth $661. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Previous 14 -0.0%
Holding current value
$661
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$60.67 - $89.12 $849 - $1,247
14 New
14 $0
Q1 2023

May 16, 2023

BUY
$41.0 - $56.12 $574 - $785
14 New
14 $0

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.69B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Kayne Anderson Rudnick Investment Management LLC Portfolio

Follow Kayne Anderson Rudnick Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kayne Anderson Rudnick Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kayne Anderson Rudnick Investment Management LLC with notifications on news.